|
US8431713B2
(en)
|
2007-01-24 |
2013-04-30 |
Array Biopharma, Inc. |
2-aminopyridine derivatives as glucokinase activators
|
|
EP2173745A2
(en)
*
|
2007-03-23 |
2010-04-14 |
Array Biopharma, Inc. |
2-aminopyridine analogs as glucokinase activators
|
|
WO2009022171A1
(en)
*
|
2007-08-13 |
2009-02-19 |
Astrazeneca Ab |
Pyridinyiioxy pyridines as alk5 inhibitors
|
|
WO2009022179A2
(en)
*
|
2007-08-14 |
2009-02-19 |
Astrazeneca Ab |
Glucokinase activators in the treatment of osteoarthritis
|
|
EP2025674A1
(de)
|
2007-08-15 |
2009-02-18 |
sanofi-aventis |
Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
|
ES2393824T3
(es)
|
2007-09-21 |
2012-12-28 |
Array Biopharma, Inc. |
Derivados de piridin-2-il-amino-1,2,4-tiadiazol como activadores de glucoquinasa para el tratamiento de diabetes mellitus
|
|
EP2195312B1
(en)
*
|
2007-10-09 |
2012-11-21 |
Merck Patent GmbH |
Pyridine derivatives useful as glucokinase activators
|
|
WO2009094427A1
(en)
|
2008-01-23 |
2009-07-30 |
Bristol-Myers Squibb Company |
4-pyridinone compounds and their use for cancer
|
|
US7741327B2
(en)
|
2008-04-16 |
2010-06-22 |
Hoffmann-La Roche Inc. |
Pyrrolidinone glucokinase activators
|
|
BRPI0920707A2
(pt)
|
2008-10-02 |
2015-12-29 |
Respivert Ltd |
compostos
|
|
WO2010058846A1
(ja)
|
2008-11-21 |
2010-05-27 |
アステラス製薬株式会社 |
４，６-ジアミノニコチンアミド化合物
|
|
WO2010067130A1
(en)
|
2008-12-11 |
2010-06-17 |
Respivert Limited |
P38 map kinase inhibitors
|
|
GB0905955D0
(en)
|
2009-04-06 |
2009-05-20 |
Respivert Ltd |
Novel compounds
|
|
GB0921730D0
(en)
|
2009-12-11 |
2010-01-27 |
Respivert Ltd |
Method of treatment
|
|
GB0921731D0
(en)
|
2009-12-11 |
2010-01-27 |
Respivert Ltd |
Theraputic uses
|
|
WO2011107494A1
(de)
|
2010-03-03 |
2011-09-09 |
Sanofi |
Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
|
|
JP5909482B2
(ja)
|
2010-03-31 |
2016-04-26 |
ザ スクリプス リサーチ インスティテュート |
細胞の再プログラム
|
|
GB201005589D0
(en)
|
2010-04-01 |
2010-05-19 |
Respivert Ltd |
Novel compounds
|
|
JP5787976B2
(ja)
|
2010-04-08 |
2015-09-30 |
レスピバート・リミテツド |
Ｐ３８ｍａｐキナーゼ阻害剤としてのピラゾリルウレア
|
|
US9024041B2
(en)
|
2010-04-08 |
2015-05-05 |
Respivert Ltd. |
P38 MAP kinase inhibitors
|
|
US8178689B2
(en)
|
2010-06-17 |
2012-05-15 |
Hoffman-La Roche Inc. |
Tricyclic compounds
|
|
EP2582709B1
(de)
|
2010-06-18 |
2018-01-24 |
Sanofi |
Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
|
|
US8530413B2
(en)
|
2010-06-21 |
2013-09-10 |
Sanofi |
Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
|
|
TW201215388A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Sa |
(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
|
|
TW201215387A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Aventis |
Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
|
|
TW201221505A
(en)
|
2010-07-05 |
2012-06-01 |
Sanofi Sa |
Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
|
|
MX344521B
(es)
|
2010-11-19 |
2016-12-19 |
Ligand Pharm Inc |
Aminas heterociclicas y sus usos.
|
|
EP2766349B1
(de)
|
2011-03-08 |
2016-06-01 |
Sanofi |
Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
|
|
EP2683704B1
(de)
|
2011-03-08 |
2014-12-17 |
Sanofi |
Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
|
US8710050B2
(en)
|
2011-03-08 |
2014-04-29 |
Sanofi |
Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
|
|
US8871758B2
(en)
|
2011-03-08 |
2014-10-28 |
Sanofi |
Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
|
|
US8828994B2
(en)
|
2011-03-08 |
2014-09-09 |
Sanofi |
Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
|
|
EP2684878A4
(en)
|
2011-03-09 |
2014-08-27 |
Daiichi Sankyo Co Ltd |
DIPYRIDYLAMINDERIVAT
|
|
CN102786517B
(zh)
*
|
2011-05-18 |
2017-06-06 |
中国医学科学院药物研究所 |
Gk和ppar双重激动活性的嘧啶噻唑胺类衍生物
|
|
JP5748210B2
(ja)
*
|
2011-05-26 |
2015-07-15 |
日本化薬株式会社 |
複素環化合物の製造方法
|
|
LT2718270T
(lt)
*
|
2011-06-10 |
2022-08-10 |
Merck Patent Gmbh |
Pirimidino ir piridino junginių, turinčių btk inhibitorinį aktyvumą, kompozicijos ir gamybos būdai
|
|
JP6061856B2
(ja)
*
|
2011-09-05 |
2017-01-18 |
中外製薬株式会社 |
クマリン誘導体の製造方法
|
|
WO2013037390A1
(en)
|
2011-09-12 |
2013-03-21 |
Sanofi |
6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
|
WO2013045413A1
(en)
|
2011-09-27 |
2013-04-04 |
Sanofi |
6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
|
TW201329067A
(zh)
*
|
2011-12-08 |
2013-07-16 |
Amgen Inc |
作為ｇｋａ活化劑之脲化合物
|
|
CN104736518B
(zh)
|
2012-05-18 |
2017-10-13 |
安进股份有限公司 |
制备噻二唑的方法
|
|
ES2616812T3
(es)
*
|
2012-11-08 |
2017-06-14 |
Bristol-Myers Squibb Company |
Compuestos piridilo sustituidos con heterociclo bicíclico útiles como moduladores de quinasa
|
|
EP2925742B1
(en)
|
2012-11-16 |
2016-10-26 |
Respivert Limited |
Kinase inhibitors
|
|
US20160031874A1
(en)
|
2013-03-13 |
2016-02-04 |
The Broad Institute, Inc. |
Substituted aminothiazoles for the treatment of tuberculosis
|
|
WO2016001341A1
(en)
*
|
2014-07-03 |
2016-01-07 |
F. Hoffmann-La Roche Ag |
Sulfonylaminopyridine compounds, compositions and methods of use
|
|
CN104610143A
(zh)
*
|
2015-02-12 |
2015-05-13 |
佛山市赛维斯医药科技有限公司 |
一种含硝基喹啉结构的葡萄糖激酶活化剂及其用途
|
|
EP3259256B1
(en)
*
|
2015-02-17 |
2022-03-09 |
Beijing Erai Therapeutics Co., Ltd. |
Compounds and methods for inducing browning of white adipose tissue
|
|
US10807983B2
(en)
|
2015-03-16 |
2020-10-20 |
Ligand Pharmaceuticals, Inc. |
Imidazo-fused heterocycles and uses thereof
|
|
EP3280401B1
(en)
*
|
2015-04-07 |
2021-08-25 |
ELA Pharma Ltd |
Compositions for treating and/or preventing cell or tissue necrosis specifically targeting cathepsin c and/or cela1 and/or cela3a and/or structurally related enzymes thereto
|
|
CA2988405A1
(en)
*
|
2015-06-11 |
2016-12-15 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
P62-zz chemical inhibitor
|
|
EP3390387B1
(en)
|
2015-12-18 |
2021-11-17 |
Bayer Pharma Aktiengesellschaft |
Heteroarylbenzimidazole compounds
|
|
WO2017207534A1
(en)
|
2016-06-03 |
2017-12-07 |
Bayer Pharma Aktiengesellschaft |
Substituted heteroarylbenzimidazole compounds
|
|
CN115448916A
(zh)
*
|
2016-10-14 |
2022-12-09 |
林伯士拉克许米公司 |
Tyk2抑制剂及其用途
|
|
US12030875B2
(en)
|
2018-09-07 |
2024-07-09 |
PIC Therapeutics, Inc. |
EIF4E inhibitors and uses thereof
|
|
KR102816656B1
(ko)
*
|
2019-06-25 |
2025-06-02 |
인벤티스바이오 컴퍼니 리미티드 |
헤테로고리 화합물, 이의 제조방법 및 이의 사용방법
|
|
CN110898049B
(zh)
*
|
2019-11-29 |
2021-09-14 |
华中师范大学 |
二硫化合物在制备药物中的应用、fbp酶抑制剂及用于预防和/或治疗糖尿病的药剂
|
|
AU2021230289A1
(en)
|
2020-03-03 |
2022-09-29 |
PIC Therapeutics, Inc. |
eIF4E inhibitors and uses thereof
|
|
WO2022147694A1
(en)
*
|
2021-01-06 |
2022-07-14 |
Beijing Erai Therapeutics Co., Ltd. |
Aminoheteroaryl compounds and uses thereof
|
|
CN118019739A
(zh)
|
2021-08-25 |
2024-05-10 |
皮克医疗公司 |
Eif4e抑制剂及其用途
|
|
JP2024534127A
(ja)
|
2021-08-25 |
2024-09-18 |
ピク セラピューティクス， インコーポレイテッド |
ｅＩＦ４Ｅ阻害剤及びその使用
|